Screening for treatment assignment based on genetic testing

What we are studying

The purpose of this study is to test any good and bad effects of several different study drugs or drug combinations, each of which targets specific genetic changes found in some cancers. The first step is to determine if you can participate in this study (screening step). The purpose of this screening step is to perform tests on your tumor biopsy to find out if you have a gene change or mutation targeted by one or more of the drugs used in this study. The tests done on your tumor are investigational, and are done for the purpose of assigning a treatment on the MATCH study. The tests are not done for any routine clinical use nor can they determine if you have a gene mutation that can be passed on in families.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 80

Eligibility Criteria

  • Histologically documented solid tumor or confirmed diagnosis of lymphoma that has progressed

What is involved

  • Study participants will have tumor biopsy tissue sent for tests to find out if you have a gene or mutation targeted by one or more drugs used in this study. If you do have a gene or mutation targeted by one or more of the drugs
  • You will asked to participate in the treatment part of this study. If you have no genetic change for which we have study drug(s) or if the available study drug(s) would put you at risk due to other health conditions
  • You will no longer be in the study.


Parking will be validated for all study related visits.

Contact Information

Study Coordinator
Sharon Averill
[email protected]

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.